stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) EPS (diluted)
United Therapeutics Corporation's EPS (diluted) for fiscal 2025 was $27.86, up 13.1% from $24.64 in fiscal 2024. Over the twelve months to 30 September 2026 it was $26.50. Over the past ten years it has ranged from −$2.39 (fiscal 2019) to $27.86 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. United Therapeutics Corporation ranks 1st of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $27.86 | 13.07% |
| FY2024 | $24.64 | 24.38% |
| FY2023 | $19.81 | 32.07% |
| FY2022 | $15.00 | 49.11% |
| FY2021 | $10.06 | (12.82%) |
| FY2020 | $11.54 | — |
| FY2019 | −$2.39 | — |
| FY2018 | $13.39 | 43.82% |
| FY2017 | $9.31 | (38.95%) |
| FY2016 | $15.25 | 19.89% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $5.71 | (21.48%) |
| Jun 2026 | $7.27 | 24.91% |
| Mar 2026 | $5.82 | (24.42%) |
| Dec 2025 | $7.70 | 7.54% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation | $26.50 |
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| ZTS Zoetis Inc. compare | $6.07 |
| TAK Takeda Pharmaceutical Co. compare | $0.66 |
| HLN Haleon PLC Sponsored ADR compare | $0.45 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $0.43 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on UTHR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement